Parkinson’s Disease (PD) is a chronic, progressive neurodegenerative condition marked by the degeneration of dopaminergic neurons in the substantia nigra region of the brain. Conventional therapeutic approaches primarily offer symptomatic management but cannot arrest or reverse the underlying neuronal loss. Emerging advancements in stem cell research, genome editing technologies, and epigenetic regulation have opened novel pathways toward developing regenerative treatments. This study explores a combined strategy that employs CRISPR/Cas9-mediated gene correction alongside epigenetic reprogramming to refine and enhance stem-cell-based interventions for Parkinson's disease (PD). Patient-specific induced pluripotent stem cells (iPSCs), harboring pathogenic variants in genes such as SNCA, LRRK2, and PARKIN, were edited using CRISPR/Cas9 technology to correct these mutations at the genomic level. Following correction, the iPSCs were directed to differentiate into functional dopaminergic neurons through controlled epigenetic modulation, utilizing histone deacetylase inhibitors and DNA methyltransferase blockers to promote lineage-specific gene expression and ensure neuronal stability. This dual intervention yielded multiple benefits: CRISPR- Based correction improved chromosomal integrity and significantly reduced the formation of toxic alpha-synuclein aggregates, while the epigenetic conditioning enhanced neuronal differentiation efficiency and synaptic connectivity in both in vitro systems and animal models of PD. Furthermore, this combinatory approach minimized risks such as tumor formation and immune incompatibility, thus reinforcing its potential for safe and effective clinical application. Altogether, the synergistic use of CRISPR gene editing and precise epigenetic remodeling offers a powerful, patient-tailored platform for regenerative therapy in Parkinson’s Disease, with the capacity to restore functional neurons and drive long-term disease modification.

Dr. Mohamed Hussein is an Assistant Professor of Biochemistry and Head of the Research Support Unit at the College of Medicine, Dubai Medical University, United Arab Emirates. He holds a PhD in Biochemistry (2017) and a Master’s degree in Biochemistry (2013) from the Faculty of Science, Egypt, along with a B.Sc. in Biochemistry (2009) from Mansoura University. He has also received PhD equivalency in Biochemistry from the UAE Ministry of Education.

Dr. Hussein has extensive research experience in molecular biology, cancer biology, immunology, and experimental therapeutics. His recent publications include contributions to Scientific Reports and the Asian Journal of Medicine and Health, with notable work on hypervitaminosis-D, immune checkpoint inhibitors in glioblastoma, and cryopreservation techniques. He has also authored book chapters in the field of cell culture technologies